Article Sidebar
Published:
Apr 4, 2017DOI:
10.4314/tjpr.v16i3.6Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Anti-trypanosomal activity of secnidazole in vitro and in vivo
Abstract
Purpose: To evaluate the anti-trypanosomal effect of secnidazole (SEC) in vitro and in vivo. Methods: The dose-response effect of SEC in Trypanosoma b. brucei infected rats was evaluated in five groups of rats (n = 5). Group A was infected but untreated; B was given diminazene aceturate (DA) (3.5 mg/kg) intraperitoneally, while groups C, D and E received orally 400, 800 and 1600 mg/kg of SEC, respectively. The effect of a combination therapy of SEC and DA was studied in 7 groups of rats (n =5). Group 1 was infected but untreated; groups 2 – 7 were treated with DA (3.5 mg/kg), while groups 3 – 7 received in addition to DA, increasing double doses of SEC (50 – 800 mg/kg).
Results: The MIC of SEC and DA were 1.4 and 0.0021 mg/ml respectively. SEC dose-dependently and significantly (p < 0.05) lowered parasitemia from day 2 post-treatment (PT) compared with infected untreated rats. Parasitemia was cleared 3 days PT in all combination groups and 5 days PT in DA group. Relapse of infection occurred in Group 2, 13 days PT, and 16 and 27 days PT in Groups 3 and 4 respectively. There was no relapse of infection in Groups 5 – 7 up to 70 days PT.
Conclusion: These results suggest that SEC possesses some degree of anti-trypanosomal effect, and that combination therapy of SEC and DA was superior to DA alone.
Keywords: Trypanosoma, Secnidazole, Diminazene aceturate, Anti-trypanosomal, Combination therapy
